Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Cartesian maps the path for an autoimmune disease cell therapy
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Biotech heads towards big catalysts
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
The next big tests for Argenx and its followers
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
The world needs Garp, according to Abbvie
After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.